Enwei Pharmaceutical Co

Enwei Pharmaceutical Co PEG

The PEG Ratio (Price/Earnings-to-Growth) of Enwei Pharmaceutical Co (301331.SZ) as of Oct 22, 2026 is 1.16.

PEG

1.16

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Enwei Pharmaceutical Co is 2025 1.16 . PEG Ratio (Price/Earnings-to-Growth) of Enwei Pharmaceutical Co was 2024 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Enwei Pharmaceutical Co Stock analysis

What does Enwei Pharmaceutical Co do? Enwei Pharmaceutical Co., Ltd. generates revenue through the research, development, production, and sales of proprietary Chinese and chemical medicines. The company's main products include Jieeryin lotion, Jieeryin ointment, Jieeryin effervescent tablets, Shanmai Jianpi oral liquid, Qingjing capsules, and Danxiong Tongmai granules, which are primarily sold via direct sales and e-commerce channels. Its focus on gynecological products, pediatric medicines, and respiratory medicines targets domestic consumers seeking specialized healthcare solutions. The firm's domestic market strategy emphasizes direct customer engagement and online sales to reach its target segments. The company's product portfolio is tailored to specific health needs, with Jieeryin products addressing gynecological concerns, Shanmai Jianpi oral liquid supporting digestive health, Qingjing capsules for gynecological treatments, and Danxiong Tongmai granules targeting cardiovascular health. These offerings are distributed through direct sales teams and e-commerce platforms, aligning with the domestic market's preference for accessible healthcare products. Enwei's domestic focus ensures that its products meet local regulatory standards and consumer demands. Enwei Pharmaceutical's revenue streams are driven by the consistent demand for its specialized medicine categories, particularly in gynecology, pediatrics, and respiratory care. The firm's domestic market presence allows it to build strong relationships with healthcare providers and end-users, facilitating repeat purchases and brand loyalty. By concentrating on these key therapeutic areas, Enwei effectively serves its core customer segments without expanding into international markets. Enwei Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Enwei Pharmaceutical Co stock

PEG Ratio (Price/Earnings-to-Growth) of Enwei Pharmaceutical Co is 1.16 in 2025.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Enwei Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Enwei Pharmaceutical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Enwei Pharmaceutical Co

All Key Metrics — Enwei Pharmaceutical Co